# US 2022/0000935 A1 · Cell-based gene therapy for neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0000935 A1
- Document ID: US20220000935A1
- Status: Published application
- Kind: A1
- Application number: 17/290,608
- Filed: 2019-11-06
- Published: 2022-01-06
- Earliest claimed: 2018-11-06
- Assignees: ALSaTECH, Inc.
- Applicants: ALSaTECH, Inc.
- Inventors: Claude NICOLAU; Claudine KIEDA; Reynald THINARD; Ruth GREFERATH; Melanie CHEVALIER
- Web page: https://patentgrep.com/patent/US20220000935A1

## CPC

- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/18: against material from animals or humans
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C12N 5/0691: {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}
- C12N 15/85: for animal cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2317/50: characterized by immunoglobulin fragments
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/01: containing a localisation/targetting motif
- C07K 2319/02: containing a signal sequence
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates, in part, to cell-based gene therapies, including those targeting, by way of non-limiting example, TDP43 and Aβ aggregates, for the use in neurodegenerative disorders, including without limitation Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease, respectively.

## Claims

### Claim 1

A method for treating or preventing a neurodegenerative disease, comprising administering to a subject a cell, the cell being a microvascular endothelial cell, or precursor thereof, engineered to release a therapeutic protein or peptide at a site of therapeutic action.

### Claim 2 (depends on 1)

The method of claim 1, wherein the therapeutic protein or peptide is an antibody or antibody fragment.

### Claim 3 (depends on 2)

The method of claim 2, wherein the antibody fragment is a Fab.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the neurodegenerative disease is selected from Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, and fronto-temporal lobar degeneration (FTLD).

### Claim 5

The method of any one of the above claims, wherein the microvascular endothelial cell or a precursor thereof is an autologous microvascular endothelial cell or a precursor thereof that is derived from the patient to whom it is administered.

### Claim 6 (depends on 5)

The method of claim 5, wherein the autologous microvascular endothelial cell or a precursor thereof is derived from the bone marrow of said patient.

### Claim 7 (depends on 5)

The method of claim 5, wherein the autologous microvascular endothelial cell or a precursor thereof is derived from the brain, the CNS, the heart, the liver, or the pancreas.

### Claim 8

The method of any one of the above claims, wherein the autologous microvascular endothelial cell or a precursor thereof is transfected with a nucleic acid vector encoding the therapeutic antibody or antibody fragment.

### Claim 9 (depends on 8)

The method of claim 8, wherein the transfection is via electroporation.

### Claim 10 (depends on 8)

The method of claim 8, wherein the transfection involves the use of the use of a cationic lipid.

### Claim 11 (depends on 8, 9, 10)

The method of any one of claims 8-10, wherein the nucleic acid vector is modified to express an insulin sequence that promotes export of the therapeutic antibody.

### Claim 12

The method of any one of the above claims, wherein the administering is by injection or infusion.

### Claim 13 (depends on 10)

The method of claim 10, wherein the injection or infusion is inferior alveolar (IA) or intravenous (IV).

### Claim 14

The method of any one of the above claims, wherein the autologous transfected cells are delivered to and/or past the blood brain barrier (BBB) and/or delivered into the brain.

### Claim 15

The method of any one of the above claims, wherein the method provides for organ-specific or early progenitors of endothelial cells to carry therapeutic antibody or antibody fragment into the brain.

### Claim 16

The method of any one of the above claims, wherein the method allows for homing properties of an autologous microvascular endothelial cell or a precursor thereof to transfer molecules in an organospecific manner.

### Claim 17

The method of any one of the above claims, wherein the therapeutic antibody or antibody fragment is directed against a protein selected from TDP43, beta-amyloid (Aβ), SOD-1, FUS/TLS, α-synuclein, Tau protein, and IAPP.

### Claim 18 (depends on 17)

The method of claim 17, wherein the therapeutic antibody or antibody fragment further comprises a targeting element for neurons.

### Claim 19

The method of any one of the above claims, wherein the site of therapeutic action is a neuron.

### Claim 20

The method of any one of the above claims, wherein the site of therapeutic action is the CNS.

### Claim 21

The method of any one of the above claims, wherein the site of therapeutic action is the brain.

### Claim 22

The method of any one of the above claims, wherein the site of therapeutic action is the liver.

### Claim 23

The method of any one of the above claims, wherein the site of therapeutic action is the pancreas or the heart.

### Claim 24

The method of any one of the above claims, wherein the cell is selected from HucPEC 55.1 (CNCM Nos. 1-4220), HucPEC 55.2 (CNCM Nos. 1-4221), HEPC.CB1, and HEPC.CB2.

### Claim 25

The method of any one of the above claims, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO: 13.

### Claim 26

The method of any one of the above claims, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO: 14.

### Claim 27

The method of any one of the above claims, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a CDR having an amino acid sequence selected from one or more of SEQ ID NOs: 19-24, optionally, wherein CDR1 is selected from SEQ ID NO: 19 or 22, wherein CDR2 is selected from SEQ ID NO: 20 or 23, wherein CDR3 is selected from SEQ ID NO: 21 or 24.

### Claim 28

The method of any one of the above claims, wherein the therapeutic protein or peptide, or antibody or antibody fragment further comprises a signal peptide of SEQ ID NO: 17 or SEQ ID NO: 18.

### Claim 29 (depends on 25, 26, 27, 28)

The method of any one of the above claims, wherein the cell comprises a nucleic acid that encodes the therapeutic protein of any one claims 25-28.

### Claim 30

The method of any one of the above claims, wherein the cell comprises a nucleic acid sequence having at least 95% identity to one of SEQ ID NOs: 1-6 or a codon optimized form thereof, optionally selected from SEQ ID NO: 1 and SEQ ID NO: 4.

### Claim 31

The method of any one of the above claims, wherein the cell comprises a nucleic acid vector comprising a nucleic acid sequence of one or more of SEQ ID NOs: 83-88, or a codon optimized form thereof.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of the claims 1-24, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO: 94.

### Claim 33 (depends on 32)

The method of claim 32, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO: 31.

### Claim 34 (depends on 32, 33)

The method of one of either claim 32 or 33, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a CDR having an amino acid sequence selected from one or more of SEQ ID NOs: 36-41, optionally, wherein CDR1 is selected from SEQ ID NO: 36 or 39, wherein CDR2 is selected from SEQ ID NO: 37 or 40, wherein CDR3 is selected from SEQ ID NO: 38 or 41.

### Claim 35 (depends on 32, 33, 34)

The method of any one of the claims 32-34, wherein the therapeutic protein or peptide, or antibody or antibody fragment further comprises a signal peptide of SEQ ID NO: 34 or SEQ ID NO: 35.

### Claim 36 (depends on 32, 33, 34, 35)

The method of any one of claims 32-35, wherein the cell comprises a nucleic acid that encodes the therapeutic protein of any one claims 32-35.

### Claim 37 (depends on 32, 33, 34, 35, 36)

The method of any one of claims 32-36, wherein the cell comprises a nucleic acid sequence having at least 95% identity to one of SEQ ID NOs: 7-12 or a codon codon optimized form thereof, optionally selected from SEQ ID NO: 7 and SEQ ID NO: 8.

### Claim 38 (depends on 32, 33, 34, 35, 36, 37)

The method of any one of claims 32-37, wherein the cell comprises a nucleic acid vector comprising a nucleic acid sequence of one or more of SEQ ID NOs: 89-93, or a codon codon optimized form thereof.

### Claim 39

A method for making a cell-based therapy for the treatment of a neurodegenerative disorder in a subject in need thereof, the method comprising:
a. obtaining a sample of cells from the subject having the neurodegenerative disorder, the sample comprising microvascular endothelial cells;
b. isolating the microvascular endothelial cells;
c. transfecting ex vivo the microvascular endothelial cells with a nucleic acid vector encoding a therapeutic protein or peptide, or antibody or antibody fragment; and
d. formulating the transfected cells for reintroduction into the subject.

### Claim 40 (depends on 39)

The method of claim 39, wherein the neurodegenerative disease is selected from Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, and fronto-temporal lobar degeneration (FTLD).

### Claim 41 (depends on 39, 40)

The method of claim 39 or 40, wherein the autologous microvascular endothelial cell sample is extracted from the bone marrow of the subject.

### Claim 42 (depends on 39, 40)

The method of claim 39 or 40, wherein the autologous microvascular endothelial cell sample is extracted from the brain, the CNS, the heart, the liver, or the pancreas.

### Claim 43 (depends on 39)

The method of claim 39, wherein the transfection is via electroporation.

### Claim 44 (depends on 39)

The method of claim 39, wherein the transfection involves the use of a cationic lipid.

### Claim 45 (depends on 39, 40, 41, 42, 43, 44)

The method of any one of claims 39-44, wherein the nucleic acid vector is modified to express an insulin sequence which promotes export of the therapeutic antibody.

### Claim 46 (depends on 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 39-45, wherein the method provides for organ-specific or early progenitors of endothelial cells to carry therapeutic antibody or antibody fragment into the brain.

### Claim 47 (depends on 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 39-46, wherein the method allows for homing properties of autologous microvascular endothelial cell or precursor thereof to transfer molecules in an organospecific manner.

### Claim 48 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 39-47, wherein the therapeutic antibody or antibody fragment is directed against a protein selected from TDP43, beta-amyloid (Aβ), SOD-1, FUS/TLS, α-synuclein, Tau protein, and IAPP.

### Claim 49 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 39-48, wherein the therapeutic antibody or antibody fragment further comprises a targeting element for neurons.

### Claim 50 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 39-49, wherein the cell is selected from HucPEC 55.1 (CNCM Nos. 1-4220), HucPEC 55.2 (CNCM Nos. 1-4221), HEPC.CB1, and HEPC.CB2.

### Claim 51 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 39-50, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO: 13.

### Claim 52 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 39-51, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO: 14.

### Claim 53 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 39-52, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a CDR having an amino acid sequence selected from one or more of SEQ ID NOs: 19-24, optionally, wherein CDR1 is selected from SEQ ID NO: 19 or 22, wherein CDR2 is selected from SEQ ID NO: 20 or 23, wherein CDR3 is selected from SEQ ID NO: 21 or 24.

### Claim 54 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 39-53, wherein the therapeutic protein or peptide, or antibody or antibody fragment further comprises a signal peptide of SEQ ID NO: 17 or SEQ ID NO: 18.

### Claim 55 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 39-54, wherein the cell comprises a nucleic acid that encodes the therapeutic protein of any one claims 51-54.

### Claim 56 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 39-55, wherein the cell comprises a nucleic acid sequence having at least 95% identity to one of SEQ ID NOs: 1-6 or a codon optimized form thereof, optionally selected from SEQ ID NO: 1 and SEQ ID NO: 4.

### Claim 57 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 39-56, wherein the cell comprises a nucleic acid vector comprising a nucleic acid sequence of one or more of SEQ ID NOs: 83-88, or a codon optimized form thereof.

### Claim 58 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 39-50, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO: 94.

### Claim 59 (depends on 58)

The method of claim 58, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO: 31.

### Claim 60 (depends on 58, 59)

The method of either claim 58 or 59, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a CDR having an amino acid sequence selected from one or more of SEQ ID NOs: 36-41, optionally, wherein CDR1 is selected from SEQ ID NO: 36 or 39, wherein CDR2 is selected from SEQ ID NO: 37 or 40, wherein CDR3 is selected from SEQ ID NO: 38 or 41.

### Claim 61 (depends on 58, 59, 60)

The method of any one of the claims 58-60, wherein the therapeutic protein or peptide, or antibody or antibody fragment further comprises a signal peptide of SEQ ID NO: 34 or SEQ ID NO: 35.

### Claim 62 (depends on 58, 59, 60, 61)

The method of any one of claims 58-61, wherein the cell comprises a nucleic acid that encodes the therapeutic protein of any one claims 58-61.

### Claim 63 (depends on 58, 59, 60, 61, 62)

The method of any one of claims 58-62, wherein the cell comprises a nucleic acid sequence having at least 95% identity to one of SEQ ID NOs: 7-12 or a codon optimized form thereof, optionally selected from SEQ ID NO: 7 and SEQ ID NO: 8.

### Claim 64 (depends on 58, 59, 60, 61, 62, 63)

The method of any one of claims 58-63, wherein the cell comprises a nucleic acid vector comprising a nucleic acid sequence of one or more of SEQ ID NOs: 89-93, or a codon optimized form thereof.

### Claim 65

An engineered cell, or precursor thereof, comprising a nucleic acid vector encoding a protein or peptide, or therapeutic antibody or antibody fragment.

### Claim 66 (depends on 65)

The engineered cell of claim 65, wherein the cell is a microvascular endothelial cell or a precursor thereof.

### Claim 67 (depends on 65, 66)

The engineered cell of either claim 65 or 66, wherein the cell or a precursor thereof is an autologous cell or precursor thereof that is derived from the patient to whom it is administered.

### Claim 68 (depends on 67)

The engineered cell of claim 67, wherein the autologous microvascular endothelial cell or a precursor thereof is derived from the bone marrow of the patient.

### Claim 69 (depends on 67)

The engineered cell of claim 67, wherein the autologous microvascular endothelial cell or a precursor thereof is derived from the brain, the CNS, the heart, the liver, or the pancreas.

### Claim 70 (depends on 65, 66, 67, 68, 69)

The engineered cell of any one of claims 65-69, wherein the antibody fragment is a Fab.

### Claim 71 (depends on 65, 66, 67, 68, 69, 70)

The engineered cell of any one of claims 65-70, wherein the nucleic acid vector is modified to express an insulin sequence which promotes export of the therapeutic protein or peptide, or antibody or fragment thereof.

### Claim 72 (depends on 65, 66, 67, 68, 69, 70, 71)

The engineered cell of any one of claims 65-71, wherein the microvascular endothelial cell is an organ-specific or early progenitor of an endothelial cell.

### Claim 73 (depends on 65, 66, 67, 68, 69, 70, 71, 72)

The engineered cell of any one of claims 65-72, further comprising homing properties that allow transfer of molecules in an organospecific manner.

### Claim 74 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73)

The engineered cell of any one of claims 65-73, wherein the therapeutic antibody or antibody fragment is directed against a protein selected from TDP43, beta-amyloid (Aβ), SOD-1, FUS/TLS, α-synuclein, Tau protein, and IAPP, or wherein the therapeutic protein or peptide is selected from one or more of nerve growth factor (NGF), apolipoprotein E (ApoE, selected from ApoE1, ApoE2, ApoE3, and ApoE4), survival motor neuron 1 (SMN1), almitoyl-protein thioesterase 1 (PPT1), CLN3/battenin, CLN6, CLN8, huntingtin, ASAP, neurturin, GDNF, BDNF, CDNF, VEGF-A, MECP2, beta-galactosidase (β-galactosidase), aromatic L-amino acid decarboxylase (AADC), SOD-1, TDP43, beta-amyloid (Aβ), FUS/TLS, α-synuclein, Tau protein, and IAPP.

### Claim 75 (depends on 74)

The engineered cell of claim 74, wherein the therapeutic antibody or antibody fragment further comprises a targeting element for neurons.

### Claim 76 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The engineered cell of any one of claims 65-75, wherein the cell is selected from HucPEC 55.1 (CNCM Nos. 1-4220), HucPEC 55.2 (CNCM Nos. 1-4221), HEPC.CB1, and HEPC.CB2.

### Claim 77 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The engineered cell of any one of claims 65-76, wherein the nucleic acid vector comprises a nucleic acid sequence having at least 95% identity to one of SEQ ID NOs: 1-6, 7, and 8.

### Claim 78 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The engineered cell of any one of the claims 65-77, wherein the vector comprises a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NOs: 13, 14, 19-24, 94, 31, 36, 37, 38, 39, 40, or 41.

### Claim 79 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The engineered cell of any one of the claims 65-78, wherein the vector comprises a nucleotide sequence of SEQ ID NOs: 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93.

### Claim 80

A therapeutic TDP43-targeting antibody comprising a peptide having an amino acid sequence at least 95% identical to SEQ ID NO: 13.

### Claim 81 (depends on 80)

The therapeutic TDP43-targeting antibody of claim 80, further comprising a peptide having an amino acid sequence at least 95% identical to SEQ ID NO: 14.

### Claim 82

A therapeutic TDP43-targeting antibody comprising one or more CDRs having an amino acid sequence selected from SEQ ID NOs: 19-24 or a variant having one or more substitutions.

### Claim 83

A therapeutic TDP43-targeting antibody comprising one or more CDRs having an amino acid sequence selected from SEQ ID NOs: 19-24.

### Claim 84 (depends on 82)

The therapeutic antibody of claim 82, comprising CDR1: SYGIS (SEQ ID NO: 19); CDR2: EIYPRRGNTYYNEKFKG (SEQ ID NO: 20); and CDR3: GGIYYGNLFDY (SEQ ID NO: 21) or a variant having one or more substitutions.

### Claim 85 (depends on 83)

The therapeutic antibody of claim 83, comprising CDR1: SYGIS (SEQ ID NO: 19); CDR2: EIYPRRGNTYYNEKFKG (SEQ ID NO: 20); and CDR3: GGIYYGNLFDY (SEQ ID NO: 21).

### Claim 86 (depends on 84, 85)

The therapeutic antibody of claim 84 or claim 85, comprising CDR1: RSSTGAVTTSNYAN (SEQ ID NO: 22); CDR2: GTNNRAP (SEQ ID NO: 23); and/or CDR3: ALWFSNHWV (SEQ ID NO: 24) or a variant having one or more substitutions.

### Claim 87 (depends on 84, 85)

The therapeutic antibody of claim 84 or claim 85, comprising CDR1: RSSTGAVTTSNYAN (SEQ ID NO: 22); CDR2: GTNNRAP (SEQ ID NO: 23); and/or CDR3: ALWFSNHWV (SEQ ID NO: 24).

### Claim 88

A therapeutic 3 amyloid-targeting antibody comprising a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO: 94.

### Claim 89 (depends on 88)

The therapeutic 3 amyloid-targeting antibody of claim 88, further comprising a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO: 31.

### Claim 90

A therapeutic 3 amyloid-targeting antibody comprising one or more CDRs having an amino acid sequence selected from SEQ ID NOs: 36-41 or a variant having one or more substitutions.

### Claim 91

A therapeutic 3 amyloid-targeting antibody comprising one or more CDRs having an amino acid sequence selected from SEQ ID Nos: 36-41.

### Claim 92 (depends on 90)

The therapeutic antibody of claim 90, comprising CDR1: NYWMN (SEQ ID NO: 36); CDR2: QIYPGDGDTNYNGKFKG (SEQ ID NO: 37); and CDR3: GDY (SEQ ID NO: 38) or a variant having one or more substitutions.

### Claim 93 (depends on 91)

The therapeutic antibody of claim 91, comprising CDR1: NYWMN (SEQ ID NO: 36); CDR2: QIYPGDGDTNYNGKFKG (SEQ ID NO: 37); and CDR3: GDY (SEQ ID NO: 38).

### Claim 94 (depends on 90)

The therapeutic antibody of claim 90, comprising CDR1: KSSQSLLNSSNQKNYLA (SEQ ID NO: 39); CDR2: FASTRES (SEQ ID NO: 40); and CDR3: QQHYNTPLT (SEQ ID NO: 41) or a variant having one or more substitutions.

### Claim 95 (depends on 90, 93)

The therapeutic antibody of claim 90 or 93, comprising CDR1: KSSQSLLNSSNQKNYLA (SEQ ID NO: 39); CDR2: FASTRES (SEQ ID NO: 40); and CDR3: QQHYNTPLT (SEQ ID NO: 41).

### Claim 96 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

An engineered cell of any of claims 65-79 or therapeutic antibody of any one of claims 80-95 for use in the delivery of an agent across the BBB.

### Claim 97 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

Use of a engineered cell of any of claims 65-79 or therapeutic antibody of any one of claims 80-95 in the manufacture of a medicament for delivery of an agent across the BBB.

### Claim 98 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

An engineered cell of any of claims 65-79 or therapeutic antibody of any one of claims 80-95 for use in the treatment of one or more neurodegenerative diseases.

### Claim 99 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

Use of an engineered cell of any of claims 65-79 or therapeutic antibody of any one of claims 80-95 in the manufacture of a medicament for treating one or more neurodegenerative diseases.
